Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
N El Rouby, JJ Lima, JA Johnson - Expert opinion on drug …, 2018 - Taylor & Francis
ABSTRACT Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of
acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some …
acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some …
dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy
DC Metz, M Vakily, T Dixit… - Alimentary pharmacology …, 2009 - Wiley Online Library
Summary Background Proton pump inhibitors (PPIs) provide the most effective
pharmacotherapy for treating acid‐related disorders. However, PPIs do not completely …
pharmacotherapy for treating acid‐related disorders. However, PPIs do not completely …
Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …
Bioequivalence and other unresolved issues in generic drug substitution
P Meredith - Clinical therapeutics, 2003 - Elsevier
Background: Substitution of generic drugs for brand-name products is highly controversial
and often is met with suspicion by health care providers and patients. Historically, the debate …
and often is met with suspicion by health care providers and patients. Historically, the debate …
Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction
Preeclampsia is a severe complication of pregnancy. Antiangiogenic factors soluble fms-like
tyrosine kinase-1 (sFlt-1) and soluble endoglin are secreted in excess from the placenta …
tyrosine kinase-1 (sFlt-1) and soluble endoglin are secreted in excess from the placenta …
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
P Soni - US Patent 9,610,272, 2017 - Google Patents
In various embodiments, the present invention provides methods of reducing the risk of a
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …
Compositions comprising EPA and obeticholic acid and methods of use thereof
JS Zakrzewski - US Patent 9,814,733, 2017 - Google Patents
US9814733B2 - Compositions comprising EPA and obeticholic acid and methods of use
thereof - Google Patents US9814733B2 - Compositions comprising EPA and obeticholic …
thereof - Google Patents US9814733B2 - Compositions comprising EPA and obeticholic …
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
M Manku, I Osterloh, P Wicker, R Braeckman… - US Patent …, 2021 - Google Patents
The present invention relates to, inter alia, pharmaceutical compositions comprising EPA
and one or more cardiovascular agents, and to therapeutic methods for treating various …
and one or more cardiovascular agents, and to therapeutic methods for treating various …
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
P Soni - US Patent 9,918,954, 2018 - Google Patents
In various embodiments, the present invention provides methods of reducing the risk of a
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
P Soni - US Patent 9,623,001, 2017 - Google Patents
In various embodiments, the present invention provides methods of reducing the risk of a
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …
cardiovascular event in a subject on statin therapy and, in particular, a method of reducing …